Investigators from Tehran University of Medical Sciences Report New Data on Diabetes Research (Utilization Trend of Parenteral Antidiabetic Drugs In Type 2 Diabetic Patients Covered By Iran Health Insurance Organization From 2011 To 2030): Diabetes Research

2023 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Researchers detail new data in Diabetes Research. According to news reporting originating from Tehran, Iran, by NewsRx correspondents, research stated, “Exploring and analyzing the cost of medicines is an important tool for their management and planning. This study aims to analyze the utilization and costs of parenteral anti-diabetic medications during the past decade and predict the future trend of these medications from 2021 to 2031 in people that are covered by Iran Health Insurance Organization (IHIO).”

Financial support for this research came from Tehran University of Medical Sciences.

Our news editors obtained a quote from the research from the Tehran University of Medical Sciences, “This study was based on secondary analysis of data routinely reported to IHIO from 2011 to 2019. For each drug, the Defined Daily Dose (DDDs) and DDDs per 1000 inhabitants per day were calculated for the last 9 years according to the WHO protocol. Then a regression analysis was used to predict the utilization trend of each drug for the following 10 years. The overall utilization of injectable antidiabetic drugs has constantly increased during the last nine years. This increasing trend is estimated to continue during the next decade. In Iran, the increase in the diabetic population and better access in the future will be the main reasons for the increase in the utilization of various insulins. The increasing trend of utilizing injectable anti-diabetic drugs in Iran might be partly due to new patients and partly because of improvement in patient access to new treatments.”

According to the news editors, the research concluded: “This also suggests that, compared to the average in the commonwealth countries, Iranian diabetic patients has faced lack of drug utilization in the past decade that is gradually reducing.”

For more information on this research see: Utilization Trend of Parenteral Antidiabetic Drugs In Type 2 Diabetic Patients Covered By Iran Health Insurance Organization From 2011 To 2030. Iranian Journal of Public Health, 2023;52(5):1071-1080. Iranian Journal of Public Health can be contacted at: Iranian Scientific Society Medical Entomology, School Public Health & Inst Health Research, Tehran Univ Medical Sciences, P O Box 6446-14155, Tehran, 00000, Iran.

The news editors report that additional information may be obtained by contacting Ali Akbari Sari, Tehran University of Medical Sciences, School of Public Health, Dept. of Health Management and Economics, Tehran, Iran. Additional authors for this research include Ali Shojaee, Rajabali Daroudi, Sayyed Masoud Shajari Pour Mousavi, Farshad Farzadfar and Majid Davari.

(Our reports deliver fact-based news of research and discoveries from around the world.)